July 10, 2026 · Hormone research in paediatrics · DOI: 10.1159/000553439

Use of teriparatide for treatment of a 3-year-old child with an activating calcium sensing receptor mutation

Listen to this summary

This case study explores the efficacy of teriparatide, an injectable PTH analogue, in treating a 3-year-old child with an activating calcium sensing receptor mutation and severe complications from standard treatment for congenital hypoparathyroidism. The authors aim to demonstrate that teriparatide can provide significant clinical improvement in young patients, addressing the limitations of current treatment options that increase the risk of kidney complications.

Stephanie Christensen, Stephanie Crossen

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play